Diplomat Pharmacy (NYSE:DPLO) updated its FY19 earnings guidance on Tuesday. The company provided EPS guidance of ($4.91-4.81) for the period, compared to the Thomson Reuters consensus EPS estimate of ($2.66). The company issued revenue guidance of $4.9-5.1 billion, compared to the consensus revenue estimate of $4.87 billion.
Several research analysts have commented on DPLO shares. Zacks Investment Research raised shares of Diplomat Pharmacy from a sell rating to a hold rating in a research note on Monday, October 14th. ValuEngine upgraded Diplomat Pharmacy from a buy rating to a strong-buy rating in a research note on Thursday, October 17th. Deutsche Bank initiated coverage on Diplomat Pharmacy in a research note on Thursday, September 12th. They set a sell rating and a $4.00 price target on the stock. Barclays set a $7.00 price target on Diplomat Pharmacy and gave the company a buy rating in a research note on Friday, August 9th. Finally, Wells Fargo & Co raised their price target on Diplomat Pharmacy from $5.00 to $5.50 and gave the company a market perform rating in a research note on Tuesday, August 13th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $9.43.
DPLO stock traded down $3.59 during trading on Tuesday, reaching $2.61. 3,724,647 shares of the company traded hands, compared to its average volume of 659,427. Diplomat Pharmacy has a 12 month low of $4.17 and a 12 month high of $17.01. The business has a 50 day simple moving average of $5.22 and a 200 day simple moving average of $5.39. The company has a market capitalization of $470.15 million, a price-to-earnings ratio of 13.05 and a beta of 1.00. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.66 and a current ratio of 0.99.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Diplomat Pharmacy had a negative net margin of 8.93% and a negative return on equity of 4.01%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.23 billion. During the same period in the previous year, the business earned ($0.05) EPS. Diplomat Pharmacy’s revenue for the quarter was down 9.1% compared to the same quarter last year. As a group, research analysts forecast that Diplomat Pharmacy will post -0.81 EPS for the current year.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Further Reading: Why do companies issue stock splits?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.